Showing results (81-90 of 4,234) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|May 13, 2021
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cellsFrancisco J Cueto, Carlos Del Fresno, Paola Brandi, et al.Journal for Immunotherapy of Cancer|August 20, 2021
Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesisYu-Fu Zhou, Shu-Shu Song, Meng-Xin Tian, et al.Journal for Immunotherapy of Cancer|August 20, 2021
Do the benefits of being a smoker hint at the existence of PD-1/PD-L1 sensitizers for patients on single-agent immunotherapy?Gintaras Zaleskis, Vita Pasukoniene, Dainius Characiejus, et al.Journal for Immunotherapy of Cancer|August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanomaSapna P Patel, Gina R Petroni, Jason Roszik, et al.Journal for Immunotherapy of Cancer|May 22, 2021
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomesJohn A Ligon, Woonyoung Choi, Gady Cojocaru, et al.Journal for Immunotherapy of Cancer|August 10, 2021
PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolismPu Sun, Xi Zhang, Rong-Jing Wang, et al.Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.Journal for Immunotherapy of Cancer|August 26, 2021
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancerChrisann Kyi, Ekaterina Doubrovina, Qin Zhou, et al.Journal for Immunotherapy of Cancer|August 3, 2021
HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trialNoor Alida Maria Bakker, Jossie Rotman, Marc van Beurden, et al.Pageof 424